Somatostatin pp 343-356 | Cite as

Treatment of Gut-Associated Neuroendocrine Tumors with the Long-Acting Somatostatin Analog, SMS 201-995

  • Gareth Williams
  • John V. Anderson
  • Stephen R. Bloom
Part of the Serono Symposia, USA book series (SERONOSYMP)


Neuroendocrine tumors associated with the gut are very rare (affecting only about 1/100,000 of the population), but are of exceptional interest from two major points of view.


Neuroendocrine Tumor Vasoactive Intestinal Polypeptide Growth Hormone Release Factor Plasma Glucagon Level Stool Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Friesen SR. Tumors of the endocrine pancreas. N Engl J Med 1982; 306: 580–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Sabate MI, Carlei F, Bloom SR, Polak JM. Endocrine tumours of the gut and pancreas. In: Polak JM, Bloom SR, eds. Endocrine tumours. The pathobiology of regulatory peptide-producing tumours. Edinburgh: Churchill-Livingstone, 1985.Google Scholar
  3. 3.
    Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Allison DJ. Therapeutic embolization. Br J Hosp Med 1978; 20: 707–15.PubMedGoogle Scholar
  5. 5.
    Adrian TE, Barnes AJ, Long RG, et al. The effect of somatostatin analogues on secretion of growth, pancreatic and gastrointestinal hormones in man. J Clin Endocrinol Metab 1981; 53: 675–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol 1985; 109: 108–14.PubMedGoogle Scholar
  7. 7.
    Bauer W, Briner U, Doepfner W, et al. A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Kraenzlin ME, Wood SM, Neufeld M, Adrian TE, Bloom SR. Effect of long acting somatostatin-analogue SMS 201–995 on gut hormone secretion in normal subjects. Experientia 1985; 41: 738–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Said SI, ed. Vasoactive intestinal peptide (Advances in peptide hormone research series). New York: Raven Press, 1982.Google Scholar
  10. 10.
    Verner JV, Morrison AB. Islet cell tumour and a syndrome of refractory watery diarrhoea and hypokalemia. Am J Med 1958; 25: 374–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Kane MG, O’Dorisio TM, Krejs GJ. Production of secretory diarrhoea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med 1983; 309: 1482–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Ruskone A, Rene E, Chayvialle JA, et al. Effect of somatostatin on diarrhoea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 1982; 27: 459–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Long RG, Barnes AJ, Adrian TE, et al. Suppression of pancreatic endocrine tumour secretion by long acting somatostatin analogue. Lancet 1979; 2: 764–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Wood SM, Kraenzlin ME, Adrian TE, Bloom SR. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: symptomatic and peptide responses. Gut 1985; 26: 438–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet 1974; 2: 1–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Sohier J, Jeanmougin M, Lombrail P, Passa P. Rapid improvement of skin lesions in glucagonomas with intravenous somatostatin infusions. Lancet 1980; 1: 40.PubMedCrossRefGoogle Scholar
  17. 17.
    Kraenzlin ME, Ch’ng JLC, Wood SM, Carr DH, Bloom SR. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185–7.PubMedGoogle Scholar
  18. 18.
    Osei K, O’Dorisio TM. Malignant insulinoma: effects of somatostatin analog (compound 201–995) on serum glucose, growth, and gastroenteropancreatic hormones. Ann Intern Med 1985; 103: 223–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J. Somatostatin inhibits diarrhoea in the carcinoid syndrome. Ann Intern Med 1980; 92: 68–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Gareth Williams
    • 1
  • John V. Anderson
    • 1
  • Stephen R. Bloom
    • 1
  1. 1.Department of MedicineRoyal Postgraduate Medical School Hammersmith HospitalLondonUK

Personalised recommendations